Literature DB >> 17516407

The long-term outcomes of human West Nile virus infection.

James J Sejvar1.   

Abstract

Since its introduction to North America in 1999, human infection with West Nile virus (WNV) has resulted in considerable acute morbidity and mortality. Although the ongoing epidemic has resulted in a great increase in our understanding of the acute clinical features of human illness and helped to define associated clinical syndromes, far less is known about potential long-term clinical and functional sequelae. Several recent assessments, however, suggest that patients--even those with apparently mild cases of acute disease--frequently have subjective, somatic complaints following WNV infection. Persistent movement disorders, cognitive complaints, and functional disability may occur after West Nile neuroinvasive disease. West Nile poliomyelitis may result in limb weakness and ongoing morbidity that is likely to be long term. Although further assessment is needed, the long-term neurological and functional sequelae of WNV infection are likely to represent a considerable source of morbidity in patients long after their recovery from acute illness.

Entities:  

Mesh:

Year:  2007        PMID: 17516407     DOI: 10.1086/518281

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  91 in total

Review 1.  The role of chemokines in the pathogenesis of neurotropic flaviviruses.

Authors:  Susana V Bardina; Jean K Lim
Journal:  Immunol Res       Date:  2012-12       Impact factor: 2.829

2.  Identification of novel host cell binding partners of Oas1b, the protein conferring resistance to flavivirus-induced disease in mice.

Authors:  S C Courtney; H Di; B M Stockman; H Liu; S V Scherbik; M A Brinton
Journal:  J Virol       Date:  2012-05-23       Impact factor: 5.103

Review 3.  Current trends in West Nile virus vaccine development.

Authors:  Ian J Amanna; Mark K Slifka
Journal:  Expert Rev Vaccines       Date:  2014-04-01       Impact factor: 5.217

4.  Demographic and clinical factors associated with persistent symptoms after West Nile virus infection.

Authors:  Robert L Cook; Xiaohui Xu; Eric J Yablonsky; Nikole Sakata; Jennifer H Tripp; Rachel Hess; Paolo Piazza; Charles R Rinaldo
Journal:  Am J Trop Med Hyg       Date:  2010-11       Impact factor: 2.345

Review 5.  West Nile virus in the transfusion setting with a special focus on Italian preventive measures adopted in 2008-2012 and their impact on blood safety.

Authors:  Simonetta Pupella; Giulio Pisani; Karen Cristiano; Liviana Catalano; Giuliano Grazzini
Journal:  Blood Transfus       Date:  2013-10-23       Impact factor: 3.443

6.  West nile virus.

Authors:  Georg Pauli; Ursula Bauerfeind; Johannes Blümel; Reinhard Burger; Christian Drosten; Albrecht Gröner; Lutz Gürtler; Margarethe Heiden; Martin Hildebrandt; Bernd Jansen; Thomas Montag-Lessing; Ruth Offergeld; Rainer Seitz; Uwe Schlenkrich; Volkmar Schottstedt; Johanna Strobel; Hannelore Willkommen
Journal:  Transfus Med Hemother       Date:  2013-07-04       Impact factor: 3.747

Review 7.  West Nile virus: A re-emerging pathogen revisited.

Authors:  Miguel A Martín-Acebes; Juan-Carlos Saiz
Journal:  World J Virol       Date:  2012-04-12

8.  West Nile virus nonstructural protein 1 inhibits TLR3 signal transduction.

Authors:  Jason R Wilson; Paola Florez de Sessions; Megan A Leon; Frank Scholle
Journal:  J Virol       Date:  2008-06-18       Impact factor: 5.103

9.  Energy metabolism during diapause in Culex pipiens mosquitoes.

Authors:  Guoli Zhou; Roger L Miesfeld
Journal:  J Insect Physiol       Date:  2008-10-17       Impact factor: 2.354

10.  Complement protein C1q reduces the stoichiometric threshold for antibody-mediated neutralization of West Nile virus.

Authors:  Erin Mehlhop; Steevenson Nelson; Christiane A Jost; Sergey Gorlatov; Syd Johnson; Daved H Fremont; Michael S Diamond; Theodore C Pierson
Journal:  Cell Host Microbe       Date:  2009-10-22       Impact factor: 21.023

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.